Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
<EQUETROTM, mechanism, Cisplatin>, <EQUETROTM, mechanism, doxorubicin HCL>, <EQUETROTM, mechanism, felbamate>, <EQUETROTM, mechanism, rifampin>, <EQUETROTM, mechanism, phenobarbital>, <EQUETROTM, mechanism, Phenytoin>, <EQUETROTM, mechanism, primidone>, <EQUETROTM, mechanism, methsuximide>, <EQUETROTM, mechanism, theophylline>